CT45A1 and lung carcinoma: Additionally, Tang et al. [27] studied the impact of siRNA knockdown of CT45A1 (cancer-testis antigen family 45 member A1) in cancer therapy and showed that depletion of CT45A1 results in significant inhibition of cell viability, migration, and invasion of lung cancer cells, accompanied by reduced expression of Bcl-2, survivin, matrix metallopeptidase (MMP)-2 and -9, phospho-ERK1/2, and phospho-cAMP-responsive element binding protein-1, along with an increase in Bax expression [27].